393 related articles for article (PubMed ID: 19908924)
1. Cost effectiveness of herpes zoster vaccine in Canada.
Najafzadeh M; Marra CA; Galanis E; Patrick DM
Pharmacoeconomics; 2009; 27(12):991-1004. PubMed ID: 19908924
[TBL] [Abstract][Full Text] [Related]
2. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.
Ultsch B; Weidemann F; Reinhold T; Siedler A; Krause G; Wichmann O
BMC Health Serv Res; 2013 Sep; 13():359. PubMed ID: 24070414
[TBL] [Abstract][Full Text] [Related]
3. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium.
Annemans L; Bresse X; Gobbo C; Papageorgiou M
J Med Econ; 2010; 13(3):537-51. PubMed ID: 20707768
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Pellissier JM; Brisson M; Levin MJ
Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
[TBL] [Abstract][Full Text] [Related]
5. Herpes zoster vaccine: A health economic evaluation for Switzerland.
Blank PR; Ademi Z; Lu X; Szucs TD; Schwenkglenks M
Hum Vaccin Immunother; 2017 Jul; 13(7):1495-1504. PubMed ID: 28481678
[TBL] [Abstract][Full Text] [Related]
6. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
[TBL] [Abstract][Full Text] [Related]
7. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.
Brisson M; Pellissier JM; Camden S; Quach C; De Wals P
Hum Vaccin; 2008; 4(3):238-45. PubMed ID: 18382137
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of the cost effectiveness of herpes zoster vaccination.
Szucs TD; Pfeil AM
Pharmacoeconomics; 2013 Feb; 31(2):125-36. PubMed ID: 23335045
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.
de Boer PT; Pouwels KB; Cox JM; Hak E; Wilschut JC; Postma MJ
Vaccine; 2013 Feb; 31(9):1276-83. PubMed ID: 23306360
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.
Le P; Rothberg MB
Ann Intern Med; 2015 Oct; 163(7):489-97. PubMed ID: 26344036
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Rothberg MB; Virapongse A; Smith KJ
Clin Infect Dis; 2007 May; 44(10):1280-8. PubMed ID: 17443464
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of vaccination against herpes zoster.
de Boer PT; Wilschut JC; Postma MJ
Hum Vaccin Immunother; 2014; 10(7):2048-61. PubMed ID: 25424815
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan.
Hoshi SL; Kondo M; Okubo I
Vaccine; 2017 May; 35(24):3264-3271. PubMed ID: 28479176
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Hornberger J; Robertus K
Ann Intern Med; 2006 Sep; 145(5):317-25. PubMed ID: 16954357
[TBL] [Abstract][Full Text] [Related]
15. Community and patient values for preventing herpes zoster.
Lieu TA; Ortega-Sanchez I; Ray GT; Rusinak D; Yih WK; Choo PW; Shui I; Kleinman K; Harpaz R; Prosser LA
Pharmacoeconomics; 2008; 26(3):235-49. PubMed ID: 18282017
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland.
Szucs TD; Kressig RW; Papageorgiou M; Kempf W; Michel JP; Fendl A; Bresse X
Hum Vaccin; 2011 Jul; 7(7):749-56. PubMed ID: 21606685
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study.
Drolet M; Zhou Z; Sauvageau C; DeWals P; Gilca V; Amini R; Bénard É; Brisson M
CMAJ; 2019 Aug; 191(34):E932-E939. PubMed ID: 31451524
[TBL] [Abstract][Full Text] [Related]
18. Aggregate health and economic burden of herpes zoster in the United States: illustrative example of a pain condition.
Harvey M; Prosser LA; Rose AM; Ortega-Sanchez IR; Harpaz R
Pain; 2020 Feb; 161(2):361-368. PubMed ID: 31599852
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.
Préaud E; Uhart M; Böhm K; Aidelsburger P; Anger D; Bianic F; Largeron N
Hum Vaccin Immunother; 2015; 11(4):884-96. PubMed ID: 25933182
[TBL] [Abstract][Full Text] [Related]
20. Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster.
Lieu TA; Ray GT; Ortega-Sanchez IR; Kleinman K; Rusinak D; Prosser LA
Pharmacoeconomics; 2009; 27(12):1005-16. PubMed ID: 19908925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]